Oxford Immunotec updates guidance after Q2 results

Oxford Immunotec Global plc (OXFD -5.8%) Q2 results: Total Revenue: $11.8M (+15.7%); Gross Profit: $5.8M (+9.4%); Operating Expenses: $11.8M (+96.7%); Operating Loss: ($6.0M) (-757.1%); Net Loss: ($6.2M) (-553.5%); Loss Per Share: ($0.36) (+14.3%); Quick Assets: $65.8M (-14.0%).

2014 Guidance: Revenue: $48M - 50M.

Q3 Guidance: Revenue: $12.4 - 12.9M.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs